127 related articles for article (PubMed ID: 23636005)
1. The Aurora kinases inhibitor VE-465 is a novel treatment for glioblastoma multiforme.
Lee PY; Chen CL; Lin ZZ; Cheng AL; Chen EI; Whang-Peng J; Huang CY
Oncology; 2013; 84(6):326-35. PubMed ID: 23636005
[TBL] [Abstract][Full Text] [Related]
2. TBK1 Inhibitor Exerts Antiproliferative Effect on Glioblastoma Multiforme Cells.
Scuderi SA; Lanza M; Casili G; Esposito F; Colarossi C; Giuffrida D; Irene P; Cuzzocrea S; Esposito E; Campolo M
Oncol Res; 2021 Sep; 28(7):779-790. PubMed ID: 33741083
[TBL] [Abstract][Full Text] [Related]
3. Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465.
Pirker C; Lötsch D; Spiegl-Kreinecker S; Jantscher F; Sutterlüty H; Micksche M; Grusch M; Berger W
Exp Dermatol; 2010 Dec; 19(12):1040-7. PubMed ID: 21087322
[TBL] [Abstract][Full Text] [Related]
4. MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme.
Sufit A; Lee-Sherick AB; DeRyckere D; Rupji M; Dwivedi B; Varella-Garcia M; Pierce AM; Kowalski J; Wang X; Frye SV; Earp HS; Keating AK; Graham DK
PLoS One; 2016; 11(10):e0165107. PubMed ID: 27783662
[TBL] [Abstract][Full Text] [Related]
5. Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells.
Pan C; Yan M; Yao J; Xu J; Long Z; Huang H; Liu Q
Oral Oncol; 2008 Jul; 44(7):639-45. PubMed ID: 17996488
[TBL] [Abstract][Full Text] [Related]
6. Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells.
Evans R; Naber C; Steffler T; Checkland T; Keats J; Maxwell C; Perry T; Chau H; Belch A; Pilarski L; Reiman T
Leuk Lymphoma; 2008 Mar; 49(3):559-69. PubMed ID: 18297535
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells.
Liu S; Tang Y; Yuan X; Yuan D; Liu J; Li B; Li Y
Invest New Drugs; 2018 Dec; 36(6):961-969. PubMed ID: 29508248
[TBL] [Abstract][Full Text] [Related]
8. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
10. The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma.
Lin ZZ; Hsu HC; Hsu CH; Yeh PY; Huang CY; Huang YF; Chen TJ; Kuo SH; Hsu C; Hu FC; Jeng YM; Chung Y; Cheng AL
J Hepatol; 2009 Mar; 50(3):518-27. PubMed ID: 19155085
[TBL] [Abstract][Full Text] [Related]
11. The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent.
Nair JS; Ho AL; Schwartz GK
Cell Cycle; 2012 Feb; 11(4):807-17. PubMed ID: 22293494
[TBL] [Abstract][Full Text] [Related]
12. Vincristine potentiates the anti-proliferative effect of an aurora kinase inhibitor, VE-465, in myeloid leukemia cells.
Yoshida K; Nagai T; Ohmine K; Uesawa M; Sripayap P; Ishida Y; Ozawa K
Biochem Pharmacol; 2011 Dec; 82(12):1884-90. PubMed ID: 21971583
[TBL] [Abstract][Full Text] [Related]
13. The potential use of tideglusib as an adjuvant radio-therapeutic treatment for glioblastoma multiforme cancer stem-like cells.
Bou-Gharios J; Assi S; Bahmad HF; Kharroubi H; Araji T; Chalhoub RM; Ballout F; Harati H; Fares Y; Abou-Kheir W
Pharmacol Rep; 2021 Feb; 73(1):227-239. PubMed ID: 33140310
[TBL] [Abstract][Full Text] [Related]
14. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells.
Yacoub A; Mitchell C; Hong Y; Gopalkrishnan RV; Su ZZ; Gupta P; Sauane M; Lebedeva IV; Curiel DT; Mahasreshti PJ; Rosenfeld MR; Broaddus WC; James CD; Grant S; Fisher PB; Dent P
Cancer Biol Ther; 2004 Aug; 3(8):739-51. PubMed ID: 15197348
[TBL] [Abstract][Full Text] [Related]
15. A dual aurora and lim kinase inhibitor reduces glioblastoma proliferation and invasion.
Rybin MJ; Laverde-Paz MJ; Suter RK; Affer M; Ayad NG; Feng Y; Zeier Z
Bioorg Med Chem Lett; 2022 Apr; 61():128614. PubMed ID: 35151865
[TBL] [Abstract][Full Text] [Related]
16. Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies.
Akahane D; Tauchi T; Okabe S; Nunoda K; Ohyashiki K
Cancer Sci; 2008 Jun; 99(6):1251-7. PubMed ID: 18429956
[TBL] [Abstract][Full Text] [Related]
17. An Aurora kinase inhibitor, AMG900, inhibits glioblastoma cell proliferation by disrupting mitotic progression.
Ryu J; Pyo J; Lee CW; Kim JE
Cancer Med; 2018 Nov; 7(11):5589-5603. PubMed ID: 30221846
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic potential of Aurora kinases targeting in glioblastoma: from preclinical research to translational oncology.
de Almeida Magalhães T; de Sousa GR; Alencastro Veiga Cruzeiro G; Tone LG; Valera ET; Borges KS
J Mol Med (Berl); 2020 Apr; 98(4):495-512. PubMed ID: 32219470
[TBL] [Abstract][Full Text] [Related]
19. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
[TBL] [Abstract][Full Text] [Related]
20. SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells.
Talarico C; Dattilo V; D'Antona L; Barone A; Amodio N; Belviso S; Musumeci F; Abbruzzese C; Bianco C; Trapasso F; Schenone S; Alcaro S; Ortuso F; Florio T; Paggi MG; Perrotti N; Amato R
Oncotarget; 2016 Mar; 7(13):15868-84. PubMed ID: 26908461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
